Data coverage, completeness and provenance for CYNATA THERAPEUTICS LIMITED in the Stock Market API — Health Care · Biotechnology.
Source date: 2026-10-30T04:59:10. Source: yfinance. Collection time is shown separately and does not establish a trade date.
| Date | Close | Currency | Source | Adjustment basis |
|---|---|---|---|---|
| 2026-10-30 | 0.0120 | AUD | yfinance | Split- and dividend-adjusted close |
| 2026-10-29 | 0.0120 | AUD | yfinance | Split- and dividend-adjusted close |
| 2026-10-28 | 0.0120 | AUD | yfinance | Split- and dividend-adjusted close |
| 2026-10-27 | 0.0110 | AUD | yfinance | Split- and dividend-adjusted close |
| 2026-10-26 | 0.0110 | AUD | yfinance | Split- and dividend-adjusted close |
GET /api/v1/companies/CYP/prices · Price parameters and adjustment semantics
Cynata Therapeutics Limited, together with its subsidiaries, engages in the development and commercialization of proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase 2 clinical trial for the treatment of graft versus host disease. It is also involved in the development of CYP-004, which is in Phase 3 clinical trial used for the treatment of osteoarthritis; CYP-006TK, a novel polymercoated silicon wound dressing for diabetic wounds; and Diabetic Foot Ulcer which has completed phase 1 trial for the treatment of non-healing wounds on the feet/lower limbs. Further, it develops Cohort 1 which has completed Phase 1/2 for the treatment of kidney transplant. Cynata Therapeutics Limited has a license arrangement with Fujifilm corporation. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013. Cynata Therapeutics Limited was incorporated in 2003 and is based in Cremorne, Australia.
Website: https://www.cynata.com · Profile fields populated: 60%
Share of stored fields populated in the anchor reporting period (FY2025), primary source yfinance. Full per-field breakdown: GET /api/v1/companies/CYP/financials.
Stored values for the most recent fiscal-year periods, with per-period field counts and the primary source each period came from. Values are shown at reported scale without interpretation.
| Period | Period end | Revenue | Net income | Total assets | Total equity | Fields populated | Source |
|---|---|---|---|---|---|---|---|
| FY2025 (AUD) | 2025-06-30 | 23 | yfinance | ||||
| FY2024 (AUD) | 2024-06-30 | 20 | yfinance | ||||
| FY2023 (AUD) | 2023-06-30 | 21 | yfinance | ||||
| FY2022 (AUD) | 2022-06-30 | 21 | yfinance |
The endpoints below describe available datasets for this listing. Missing fields remain unknown. Free API keys — no card required.
Name, sector, industry, HQ, employees, market cap, source-tagged.
GET /api/v1/companies/CYP
Multi-year statements with per-field source tags and completeness.
GET /api/v1/companies/CYP/financials
P/E, P/B, ROE, ROA, margins, EPS, debt/equity — formulas documented.
GET /api/v1/companies/CYP/metrics/summary
Report PDFs with LLM-ready markdown conversions where available.
GET /api/v1/companies/CYP/filings
Dated press releases and announcements with source links.
GET /api/v1/companies/CYP/news
Create a free key, then:
curl -H "X-API-Key: KEY" https://stockmarketapi.ai/api/v1/companies/CYP
Free tier — instant API key. Built for AI agents.